Table 3.
Radiographic and clinical patient outcomes.
| Variable | Patients, % (N = 16) |
|---|---|
| 5-ALA-related toxicity | 0 (0) |
| Residual contrast enhancement on postoperative MRI | 13 (81.3) |
| Residual volume, cc (mean, SD) | 1.16 ± 1.11 |
| Percent extent of resection (EOR, mean, SD) | 91.5 ± 10.7 |
| Chemotherapy or radiation received | 15 (93.8) |
| Total clinical follow-up, months (mean, SD) | 5.7 ± 4.4 |
| New neurological deficit | 4 (26.7) |
| mRS | 2.3 ± 1.3 |
| Karnofsky score | 71.9 ± 22.1 |
| NIHSS | 3.9 ± 2.4 |
| Total radiographic follow-up, months (mean, SD) | 3.8 ± 3.1 |
| Radiographic recurrence or progression | 8 (50.0) |
| Time to recurrence or progression, months (mean, SD)$ | 5 ± 3 |
| Mortality | 6 (37.5) |
| Time to mortality, months (mean, SD)# | 6.3 ± 4.9 |
| 6-month progression-free survival@ | 6 (46.2) |
Missing data:
$
Out of 4 patients that had recurrence/progression.
#
Out of 3 patients that died.
@
Missing 2 patients operated on <6 months ago.